BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36094928)

  • 1. Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients.
    Mighri N; Mejri N; Boujemaa M; Berrazega Y; Rachdi H; El Benna H; Labidi S; Benna F; Boubaker S; Boussen H; Abdelhak S; Hamdi Y
    PLoS One; 2022; 17(9):e0269732. PubMed ID: 36094928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p53 protein product in triple negative breast cancers and relation with clinical and histopathological parameters.
    Jasar D; Smichkoska S; Kubelka K; Filipovski V; Petrushevska G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):69-79. PubMed ID: 26076776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
    Pan Y; Yuan Y; Liu G; Wei Y
    PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer in young women from a low risk population in Nepal.
    Thapa B; Singh Y; Sayami P; Shrestha UK; Sapkota R; Sayami G
    Asian Pac J Cancer Prev; 2013; 14(9):5095-9. PubMed ID: 24175782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
    Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
    Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: A clinico-epidemiological and histopronostic study of 90 cases.
    Darouich S; El Amine El Hadj O; Betaieb I; Goucha A; Dhiab T; Rahal K; Gamoudi A; El May A
    Tunis Med; 2017 Jan; 95(1):37-44. PubMed ID: 29327767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
    Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
    J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of molecular classification of breast cancer on the safety of breast-conserving surgery].
    Li Y; Mu L; Ruan YX; Wang YT; Zhang D; Zhou H; Wang X
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):341-346. PubMed ID: 29860760
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
    Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
    Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
    Hao S; He ZX; Yu KD; Yang WT; Shao ZM
    Oncotarget; 2016 Apr; 7(17):24824-31. PubMed ID: 27050075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
    Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
    BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in breast cancer prognosis: molecular predictors of treatment response and survival.
    Foo EM; Boost MV; Wong AS; Loo WT; Chow LW; Chow CY
    Int J Biol Markers; 2013 Jun; 28(2):131-40. PubMed ID: 23709349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.